N/A N=570 Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy
Varicocele
Primary: Recurrent Varicocele — 2; 16 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome
Pelvic Congestion Syndrome
Primary: Change in Pain Scale — 47; 48; 2; 2 participants — p=>0.999
Phase 3 N=117 Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
Phase 3 N=235 Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
Phase 3 N=279 Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
Phase 2 N=60 Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
Varicose Veins
Primary: Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects — 0 participants
Phase 2 N=16 An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
Varicose Veins
Primary: Responders to Treatment, Assessed by Duplex Ultrasound — 9 participants
N/A N=112 SeCure Endovenous Laser Treatment Study
Chronic Venous Insufficiency
Primary: Acute Primary Ablation Success — 96 Veins
N/A N=27 Venclose RF Ablation System for the Treatment of IPVs
Chronic Venous Insufficiency
Primary: Safety: AEs, SAEs, ADEs, SADEs, UADEs — 0; 0; 0; 0 Events
N/A N=242 VenaSeal Sapheon Closure System Pivotal Study (VeClose)
Great Saphenous Vein (GSV) With Venous Reflux Disease
Primary: Number of Participants With Complete Closure of the Target Vein at 3 Months — 107; 109 Participants — p=<0.0001
N/A N=25 EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence
Chronic Venous Insufficiency
Primary: Vein Occlusion Rate — 29; 0; 0 limbs
N/A N=43 Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins
Venous Insufficiency
Primary: Primary Effectiveness Objective — 53; 66 Treated IPVs
N/A N=120 Prevention of Lymphoceles After Robotic PLND
Lymphoceles · Prostate Cancer
Primary: Incidence of Lymphoceles — 10; 12; 104; 102 participants — p=0.412
N/A N=110 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
Phase 1 N=21 Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)
Varicose Veins
Primary: Weight-adjusted Polidocanol Cmax (Serum) — 584.1; 1188.7; 840.7; 1189.6 ng/mL
N/A N=33 Vasculaire Compression System Increases Flow Velocity in the Femoral Vein
Venous Thrombosis
Primary: Change in Femoral Venous Peak Flow Velocity Compared to Resting Baseline — 18.9 cm/s — p=<0.0001
N/A N=76 Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
Phase 3 N=77 Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
Varicose Veins
Primary: The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks — 16.7; 30.7 units on a scale
N/A N=170 BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
May-Thurner Syndrome · Peripheral Vascular Disease · Venous Disease
Primary: Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure — 128 Participants — p=0.0001
N/A N=243 VIVO Clinical Study
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
Primary: Number of Participants With 30-day Freedom From Major Adverse Events — 232 Participants — p=<0.0001
N/A N=280 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
N/A N=280 The SHUNT-V Study for Varices
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants